Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

IRONWOOD PHARMACEUTICALS, INC.

(IRWD)
  Report
Real-time Estimate Cboe BZX  -  01:35:34 2023-02-07 pm EST
11.37 USD   -1.09%
02/02Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
BU
01/11Transcript : Ironwood Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 09:00 AM
CI
01/09Insider Sell: Ironwood Pharmaceuticals
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference

11/22/2022 | 04:03pm EST

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 4:30 p.m. ET at the Lotte New York Palace.

A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.


ę Business Wire 2022
All news about IRONWOOD PHARMACEUTICALS, INC.
02/02Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
BU
01/11Transcript : Ironwood Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morg..
CI
01/09Insider Sell: Ironwood Pharmaceuticals
MT
01/09Ironwood Pharmaceuticals Lowers Full-Year 2022 Revenue Guidance; Issues 2023 Revenue Ou..
MT
01/09Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY..
BU
01/09Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023
CI
01/09Ironwood Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2022
CI
01/04Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conferenc..
BU
2022Insider Sell: Ironwood Pharmaceuticals
MT
2022AbbVie Submits Supplemental NDA for Use of Linaclotide in Children, Adolescents With Fu..
MT
More news
Analyst Recommendations on IRONWOOD PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 419 M - -
Net income 2022 178 M - -
Net cash 2022 275 M - -
P/E ratio 2022 11,8x
Yield 2022 -
Capitalization 1 763 M 1 763 M -
EV / Sales 2022 3,55x
EV / Sales 2023 2,74x
Nbr of Employees 219
Free-Float 98,4%
Chart IRONWOOD PHARMACEUTICALS, INC.
Duration : Period :
Ironwood Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IRONWOOD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 11,49 $
Average target price 13,60 $
Spread / Average Target 18,4%
EPS Revisions
Managers and Directors
Thomas A. McCourt President, Chief Executive Officer & Director
Sravan Kumar Emany Chief Financial Officer & Senior Vice President
Julie Harris McHugh Executive Chairman
Michael Shetzline Chief Medical Officer & Senior Vice President
Marcel Moulaison Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
IRONWOOD PHARMACEUTICALS, INC.-7.26%1 763
MODERNA, INC.-5.21%65 414
LONZA GROUP AG22.89%44 540
IQVIA HOLDINGS INC.13.38%43 149
ALNYLAM PHARMACEUTICALS, INC.-1.80%27 576
SEAGEN INC.5.83%25 250